This content is restricted to registered user. If you are an existing user, please log in. New users may register for free.
Novartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
Novartis announced that the US Food and Drug Administration (FDA) has approved a label update for Cosentyx® (secukinumab), the first interleukin-17A (IL-17A) antagonist approved to treat moderate to severe plaque psoriasis.1 The
